Estrella Immunopharma (NASDAQ: ESLA) — Perfil da empresa, notícias e dados financeiros
Estrella Immunopharma is focused on immunotherapies, developing treatments to enhance immune response for cancer and autoimmune diseases.
Estrella Immunopharma
Estrella Immunopharma (NASDAQ:ESLA) focuses on advancing healthcare through innovative pharmaceutical solutions, with a keen interest in developing immunotherapies. The company is devoted to creating treatments that enhance the body's immune response to various diseases, emphasizing cancer and autoimmune disorders. Estrella Immunopharma's objectives are to push the boundaries of medical science, aiming for breakthroughs that can significantly improve patient outcomes. Through rigorous research and clinical trials, the company seeks to uncover new therapeutic avenues that can offer hope to those facing challenging diagnoses.
Resumo
Operações
Produtos e/ou serviços de Estrella Immunopharma
- Development of novel cancer immunotherapies targeting resistant tumors, employing cutting-edge biotechnology for increased efficacy.
- Production of proprietary therapeutic antibodies aimed at specific cancer markers, enhancing precision medicine in oncology.
- Collaboration on a groundbreaking vaccine project focused on preventing recurrences in high-risk cancer patients, leveraging immune system modulation.
- Initiation of clinical trials for a unique gene therapy approach aimed at correcting immune dysfunctions in rare diseases, pioneering personalized treatments.
- Offering comprehensive diagnostic services that utilize advanced molecular techniques to identify suitable immunotherapeutic strategies for individual patients.
- Research and development of innovative immune modulators intended to enhance the efficacy of existing cancer treatments, addressing unmet medical needs.
equipe executiva do Estrella Immunopharma
- Cheng LiuCEO, President & Director
- Jiandong XuChief Financial Officer
Principais indicadores financeiros
Resultados divulgados pela Estrella Immunopharma, em USD.
- Cap. de mercado
- 40,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -13,1 mi | -13,1 mi | |
| — | -8,8 mi | -8,8 mi | |
| 0 | -7,3 mi | -7,3 mi | |
| 0 | -11,1 mi | -11,1 mi |